Patents Assigned to Nihon Medi-Physics Co., Ltd.
  • Publication number: 20200009273
    Abstract: There is provided a labeling precursor compound represented by the general formula (2): wherein S represents a substrate, L represents a straight alkyl group having 1 to 6 carbon atoms which may contain an ether group, R1 and R2 each independently represent a straight or branched alkyl group having 1 to 30 carbon atoms, or a substituted or unsubstituted monocyclic or condensed polycyclic aryl group, R3 each independently represent an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms, and p represents an integer of 0 to 4.
    Type: Application
    Filed: March 5, 2018
    Publication date: January 9, 2020
    Applicants: NIHON MEDI-PHYSICS CO., LTD., TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Masato KIRIU, Hiroaki ICHIKAWA, Yuki OKUMURA, Hiroshi TANAKA
  • Patent number: 10472338
    Abstract: Provided is a method for producing flutemetamol including the steps of: reacting a precursor compound represented by a predetermined general formula with a radioactive fluoride to obtain a 18F labeling compound represented by a predetermined general formula; allowing a strong base to act on the reaction mixture of the above step containing the precursor compound and the 18F labeling compound; after the above step, purifying the 18F labeling compound using a reverse phase solid phase extraction cartridge; and removing a protective group to obtain [18F]flutemetamol.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: November 12, 2019
    Assignees: GE HEALTHCARE LIMITED, NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Yuki Okumura, Gota Tonoya, Tomoyuki Matsunami
  • Publication number: 20190276411
    Abstract: A simple method for producing a clinically applicable radiopharmaceutical composition containing 1-(2,2-dihydroxymethyl-3-[18F]fluoropropyl)-2-nitroimidazole ([18F]DiFA) or a salt thereof as an active ingredient, is provided which includes a synthesis step of obtaining a crude product of [18F]DiFA from a labeling precursor compound for [18F]DiFA; and a purification step of purifying the crude product, in which the purification step includes purifying [18F]DiFA using two or more different types of reverse phase solid phase extraction cartridges.
    Type: Application
    Filed: February 28, 2019
    Publication date: September 12, 2019
    Applicants: Nihon Medi-Physics Co., Ltd., National University Corporation Hokkaido University
    Inventors: Masato Kiriu, Soichi Nakamura, Yuji Kuge, Norifumi Abo
  • Patent number: 10395364
    Abstract: One embodiment of the present invention addresses the problem of reducing the influence of physiological accumulation in monitoring nuclear medical image data. To solve this problem, the embodiment includes: extracting a bone area from CT image data having been positioned with nuclear medical image data; in the nuclear medical image data, displaying the data of an area overlapping the bone area extracted above; and, in the nuclear medical image data, not displaying the data of an area not overlapping the bone area extracted above.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: August 27, 2019
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Kazuo Hamada, Hiromitsu Daisaki, Kazumasa Nishida
  • Publication number: 20190255199
    Abstract: The present invention addresses the problem of providing a technique for detecting a lesion of a heart disease in a non-invasive manner. The present invention provides a non-invasive diagnostic imaging agent for a heart disease, which contains a radioactively labeled compound capable of binding to an aldosterone synthase or a salt thereof as an active ingredient.
    Type: Application
    Filed: June 9, 2017
    Publication date: August 22, 2019
    Applicant: Nihon Medi-Physics Co., Ltd.
    Inventor: Yoshifumi MAYA
  • Patent number: 10366479
    Abstract: [Problem to be Solved] To improve stability of automatic normalization of a bone scintigraphy image. [Solution] A preferred embodiment includes: creating a pixel value histogram of image data representing a bone scintigraphy image; setting a plurality of thresholds related to pixel values based on the pixel value histogram; calculating respective average pixel values for the set thresholds; arranging the calculated average pixel values in order from the largest value; and determining a reference value for normalizing the image data based on at least part of a set of the average pixel values arranged in the order. The determining the reference value includes: determining one straight line that approximates a region of small average pixel values out of the set of the average pixel values arranged in the order; and calculating the reference value based on the straight line.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: July 30, 2019
    Assignee: Nihon Medi-Physics Co. Ltd.
    Inventor: Kazuhiro Nishikawa
  • Patent number: 10358434
    Abstract: Provided is a medicament comprising the compound represented by the following general formula (1) or a salt thereof: In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined. Methods for producing various radioactive compounds are also provided.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 23, 2019
    Assignees: NIHON MEDI-PHYSICS CO., LTD., KYOTO UNIVERSITY, NATIONAL HOSPITAL ORGANIZATION
    Inventors: Akihiro Izawa, Kei Akama, Yuki Okumura, Yurie Fukui, Nobuya Kobashi, Tsutomu Abe, Yoshihiro Doi, Miho Ikenaga, Hideo Saji, Hiroyuki Kimura, Mitsuhide Naruse
  • Publication number: 20190169169
    Abstract: Provided is a medicament comprising the compound represented by the following general formula (1) or a salt thereof: In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined. Methods for producing various radioactive compounds are also provided.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 6, 2019
    Applicants: NIHON MEDI-PHYSICS CO., LTD., Kyoto University, National Hospital Organization
    Inventors: Akihiro IZAWA, Kei AKAMA, Yuki OKUMURA, Yurie FUKUI, Nobuya KOBASHI, Tsutomu ABE, Yoshihiro DOI, Miho IKENAGA, Hideo SAJI, Hiroyuki KIMURA, Mitsuhide NARUSE
  • Patent number: 10258247
    Abstract: Provided is a highly reliable technique for the evaluation of ischemic conditions. A preferred embodiment is a nuclear medicine measurement protocol in which the administration of a radiopharmaceutical agent and radiation measurement are performed twice at rest and under stress. In the nuclear medicine measurement protocol, radiation collection is performed without radiopharmaceutical agent administration before the second radiopharmaceutical agent administration, and the result is used to correct the nuclear medicine measurement result after the second radiopharmaceutical agent administration.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: April 16, 2019
    Assignee: Nihon Medi-Physics Co. Ltd.
    Inventors: Kazumasa Nishida, Kazuo Hamada, Kazunori Kobayashi
  • Publication number: 20190055207
    Abstract: Provided is a method for producing flutemetamol including the steps of: reacting a precursor compound represented by a predetermined general formula with a radioactive fluoride to obtain a 18F labeling compound represented by a predetermined general formula; allowing a strong base to act on the reaction mixture of the above step containing the precursor compound and the 18F labeling compound; after the above step, purifying the 18F labeling compound using a reverse phase solid phase extraction cartridge; and removing a protective group to obtain [18F]flutemetamol.
    Type: Application
    Filed: October 17, 2016
    Publication date: February 21, 2019
    Applicants: GE Healthcare Limited, Nihon Medi-Physics Co., Ltd.
    Inventors: Yuki Okumura, Gota Tonoya, Tomoyuki Matsunami
  • Patent number: 10189815
    Abstract: Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: January 29, 2019
    Assignees: NIHON MEDI-PHYSICS CO., LTD., KYOTO UNIVERSITY, NATIONAL HOSPITAL ORGANIZATION
    Inventors: Akihiro Izawa, Kei Akama, Yuki Okumura, Yurie Fukui, Nobuya Kobashi, Tsutomu Abe, Yoshihiro Doi, Miho Ikenaga, Hideo Saji, Hiroyuki Kimura, Mitsuhide Naruse
  • Patent number: 10081630
    Abstract: The present invention relates to a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof, or a radiopharmaceutical comprising the same.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: September 25, 2018
    Assignees: KYOTO UNIVERSITY, NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Masahiro Ono, Hideo Saji, Masafumi Ihara, Hiroki Matsumoto, Ikuya Seki
  • Patent number: 10081620
    Abstract: There is provided a labeling precursor compound represented by the following general formula (2): wherein R1 represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R2 and R3 each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R6 represents an alkyl group or —CONR11R12 wherein R11 and R12 each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R4, R5, R7 and R8 each independently represent a hydrogen atom, an alkyl group or an alkoxy group.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: September 25, 2018
    Assignees: NIHON MEDI-PHYSICS CO., LTD., TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Masahito Toyama, Masato Kiriu, Hiroshi Tanaka
  • Patent number: 10080812
    Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: September 25, 2018
    Assignees: KYOTO UNIVERSITY, NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Hideo Saji, Masahiro Ono, Masafumi Ihara, Ikuya Seki
  • Patent number: 10055665
    Abstract: In imaging analysis of a living body, a Region Of Interest (ROI) is set on the basis of the state of radiopharmaceutical accumulation. An example for setting an ROI includes: performing first transformation for anatomically standardizing, with the use of a positive template, a nuclear medicine image acquired by applying a radiopharmaceutical to a subject; performing second transformation for anatomically standardizing, with the use of a negative template, the nuclear medicine image; calculating a degree of similarity between a first anatomical standardization image acquired by the first transformation and the positive template; calculating a degree of similarity between a second anatomical standardization image acquired by the second transformation and the negative template; and applying, to an ROI template, inverse transformation of the first transformation or the second transformation, whichever has the higher of the calculated degrees of similarity, in order to set the ROI.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: August 21, 2018
    Assignees: Nihon Medi-Physics Co., Ltd., Foundation for Biomedical Research and Innovation at Kobe
    Inventors: Go Akamatsu, Michio Senda, Yasuhiko Ikari, Shuya Miki
  • Publication number: 20180193493
    Abstract: Provided is a method for imaging a renal lesion comprising the steps of administrating a nitroimidazole-based compound to a living body and obtaining an image of the renal lesion by detecting radiation non-invasively from the outside of the living body wherein the renal imaging agent comprises a defined nitroimidazole-based compound or a salt thereof. The step of obtaining the image of the renal lesion can include using positron emission tomography.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 12, 2018
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventor: Norihito NAKATA
  • Patent number: 10010632
    Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: July 3, 2018
    Assignee: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Osamu Ito, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
  • Publication number: 20180170822
    Abstract: An apparatus for producing a radiolabeled compound is a production apparatus which produces a radiolabeled compound by introducing a radioisotope into a non-radioactive labeling precursor compound. The production apparatus includes a solid phase extraction unit in which a specific process which is a reaction of an intermediate compound, a purification of the intermediate compound, or a purification of the radiolabeled compound is carried out; and a cooling unit that cools the solid phase extraction unit, when the specific process is carried out.
    Type: Application
    Filed: May 13, 2016
    Publication date: June 21, 2018
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Daisaku NAKAMURA, Masahito TOYAMA, Kei AKAMA, Hideaki EHARA
  • Publication number: 20180161463
    Abstract: There is provided a diagnostic imaging agent for early bone metastasis from cancer, containing trans-1-amino-[18F]fluorocyclobutanecarboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: June 1, 2016
    Publication date: June 14, 2018
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Shuntaro OKA, Masaru KANAGAWA, Akiharu OTAKA, Masako TERAMACHI, Satoshi WATANABE, Toshie NAGATOMO
  • Publication number: 20180000974
    Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.
    Type: Application
    Filed: February 24, 2016
    Publication date: January 4, 2018
    Applicants: KYOTO UNIVERSITY, NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Hideo SAJI, Masahiro ONO, Masafumi IHARA, Ikuya SEKI